Homemade stent shields: fortifying against coronary perforation in STEMI patients amidst intensive glycoprotein

Muhammad Imran Hanif1, Minahil Tariq Sheikh1

  • 1Department of Cardiology, Gulab Devi Chest Hospital, Ferozepur Road, Lahore 54000, Pakistan.

PubMed

Insights

Coronary artery perforation (CAP) during percutaneous coronary intervention (PCI) can be managed with an improvised covered stent when commercial options are unavailable. This case demonstrates the feasibility and safety of this novel approach in a STEMI patient.

Area of Science:

  • Interventional Cardiology
  • Cardiovascular Medicine
  • Medical Device Innovation

Background:

  • Coronary artery perforation (CAP) is a rare but serious complication during percutaneous coronary intervention (PCI).
  • Prompt management is crucial, typically involving covered stents to seal the perforation.
  • Improvised covered stents offer an alternative when commercial devices are unavailable.

Observation:

  • A 70-year-old male with myocardial infarction underwent primary PCI.
  • The procedure resulted in CAP, leading to cardiac tamponade, managed with pericardiocentesis.
  • A commercial covered stent was unavailable; an improvised one was successfully deployed.

Findings:

  • The improvised covered stent effectively sealed the coronary artery perforation.
  • The patient received glycoprotein IIb/IIIa inhibitors and heparin for acute stent thrombosis.
  • Hemodynamic status stabilized, and the patient was discharged in stable condition.

Implications:

  • This case highlights the feasibility and safety of using homemade covered stents in managing CAP.
  • Improvised stenting techniques may be a viable option in complex PCI, especially in resource-limited settings.
  • Further research could validate this approach, expanding treatment options for coronary artery perforation.
Abstract

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...